Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep;22(9):1278.
doi: 10.1016/S1473-3099(22)00495-9. Epub 2022 Jul 18.

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab

Maxime Hentzien  1 , Brigitte Autran  2 , Lionel Piroth  3 , Yazdan Yazdanpanah  4 , Alexandra Calmy  5
Affiliations
Comment

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab

Maxime Hentzien et al. Lancet Infect Dis. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

MH has received honoraria for educational events from Gilead, and support for attending meetings from Gilead and Pfizer. LP is a member of Pfizer's scientific board on antibiotics and receives support for attending meetings from Gilead, Merck, and Menarini. AC has received research grants from Merck, AbbVie, Gilead, Viiv Healthcare, and meeting support from Gilead. All other authors declare no competing interests.

Comment in

Comment on

References

    1. Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. - PMC - PubMed
    1. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 doi: 10.1038/s41586-022-04980-y. published online June 17. - DOI - PMC - PubMed
    1. Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. MedRxiv. 2022 doi: 10.1101/2022.03.10.22272100. (preprint). - DOI
    1. FDA Coronavirus (COVID-19) update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against omicron variant. 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19...
    1. Lilly Investors Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options. https://investor.lilly.com/news-releases/news-release-details/lilly-will...